Clinical Trial

Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 9, 2023 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
This study is a multi-center, single-arm, open-label phase II clinical trial, aiming to observe and evaluate the perioperative treatment of tislelizumab combined with chemotherapy (CAPOX) in stage II or III colorectal cancer with MSI-H/dMMR Patient efficacy and safety.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-04-23.
Trial Details
NCT Number NCT05841134
Lead Sponsor The First Affiliated Hospital of Zhengzhou University
Conditions MSI-H Colorectal Cancer, Tislelizumab, Oxaliplatin, Capecitabine
Enrollment 25 participants
Start Date 2023-06-01
Primary Completion 2024-12-31 (estimated)
Study Completion 2027-01-31 (estimated)
Updated on ClinicalTrials.gov 2023-05-09